Assessment of locomotive syndrome in patients with visceral cancer, the comparison with non-cancer patients using propensity score matching
Assessment of locomotive syndrome in patients with visceral cancer, the comparison with non-cancer patients using propensity score matching
复制标题
DOI：
10.1016/j.jos.2021.07.018
复制
发表时间：
2022-11-02
影响因子：
1.7
通讯作者：
Ohtori, Seiji
中科院分区：
文献类型：
--
作者：
Sato, Masashi;Furuya, Takeo;Ohtori, Seiji
背景：当治疗癌症患者时，症状的进展伴随着全身状况和运动功能的恶化。从风险-收益的角度来看，必须保持一定水平的身体功能才能继续癌症治疗。最近，癌症门诊治疗变得越来越普遍。运动功能对于确定继续癌症治疗的可行性很重要。本研究旨在使用日本骨科协会制定的运动功能测试评估内脏癌患者的运动功能。方法：进行局部试验，并将结果与非癌症个体的数据进行比较。背景数据通过倾向评分匹配进行匹配。将53例癌症患者（C组）和75例非癌症患者（N组）的资料进行比较。结果：C组两步测验平均分低于N组（1.27：1.37，p = 0.004）。C组站立试验的平均功能差于N组（p = 0.001）。老年运动功能量表（GLFS）平均分C组明显高于N组（19.92：5.29，SE 2.21，p <0.001）。较高的25个问题GLFS分数表明移动性降低。C组中Ⅱ期的比例显著高于N组（51%：13%，p <0.001）。两次现场试验的结果显示，两组之间的临床差异极小，但具有统计学显著性差异。运动功能明显维持的门诊癌症患者中，局部试验可检测潜在的运动功能障碍。结论：即使是在门诊的癌症患者中，他们的运动功能也可能受损。维持和增强癌症患者运动功能的治疗干预可能有助于继续癌症治疗，并改善预后。(C)2021年日本骨科协会。Elsevier B.V.出版，保留所有权利。
Background: When treating cancer patients, the progression of symptoms is accompanied by the deterioration of systemic conditions and motor function. From a risk-benefit perspective, a certain level of physical function must be maintained to continue cancer treatment. Recently, outpatient cancer treatment has become more common. Motor function is important to determine the feasibility of continuing cancer treatment. The study aimed to evaluate the motor function of patients with visceral cancer using locomo tests established by Japanese Orthopaedic Association. Methods: Locomo tests were performed, and the results were compared with data from non-cancer individuals. Background data were matched by propensity score matching. Data from 53 cancer pa-tients (group C) were compared with that of 75 non-cancer patients (group N). Results: The average score in the two-step test of group C was lower than that of group N (1.27: 1.37, p = 0.004). The average function in the stand-up test of group C was worse than that of group N (p = 0.001). The average score in the 25-question geriatric locomotive function scale (GLFS) of group C was significantly higher than that of group N (19.92: 5.29, SE 2.21, p < 0.001). Higher 25-question GLFS scores indicate reduced mobility. The proportion of the locomo stage 2 in group C was significantly higher than in group N (51%: 13%, p < 0.001). The results of the two field tests revealed a clinically minimal difference between the two groups, but a statistically significant difference. Locomo tests may be detect potential motor dysfunction in outpatient cancer patients with apparently maintained motor function. Conclusions: Even in cancer patients who attend outpatient clinics, their motor functions could be potentially impaired. Therapeutic interventions to maintain and enhance motor function for cancer patients could be useful for continuing cancer treatment, and furthermore, improving prognosis. (C) 2021 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.